(Date:12/3/2009)... Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ... compounds for the treatment of cardiovascular and metabolic disease, ... visit in its Phase 2 FDG-PET clinical trial of ... and was carried out at five sites in the ...
(Date:12/3/2009)... (NYSE: IMA ), a global leader in enabling ... the merger of rapid diagnostics and health management, has declared ... Convertible Perpetual Preferred Stock ( IMA-PB). The dividend will be ... per share equal to the quotient of (a) $3.00 divided ...
(Date:12/2/2009)... MATK ) announced today that it intends to release ... on December 16, 2009, at approximately 4:00 p.m. Eastern Time ... will conduct a conference call to discuss these results with ... live via webcast by visiting Martek,s web site at ...
(Date:12/2/2009)... YORK, Dec. 2 Reportlinker.com announces that ... in its catalogue: ,, Carbondioxide Incubators ... http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators are ... genetics, cancer, research, and other applications for ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4